Modulation of NNMT-SIRT1 interactions, optimization of combination therapies, and targeted inhibition of RUNX2-driven signaling pathways could serve as valuable strategies to enhance treatment efficacy and overcome chemoresistance in osteosarcoma. This evidence concerns the gene SIRT1 and osteosarcoma.